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OBJECTIVE: The aim of this study was to identify the participation of the coagulation system in the differential diagnosis of 
pleural effusions.
INTRODUCTION: Imbalance between immunologic and metabolic factors triggers a sequence of events resulting in pleural re-
actions and accumulation of fluid. The coagulation system, which is fundamental for the maintenance of homeostasis, contributes 
to the inflammatory process responsible for pleural effusions, and participates in cellular proliferation and migration as well as in 
the synthesis of inflammatory mediators.
METHODS: We evaluated the laboratory profile of coagulation and fibrinolysis in 54 pleural fluids (15 transudates and 39 exudates).
RESULTS: The coagulation system acts according to the pathophysiologic mechanisms involved in the development of pleural 
effusions. In inflammatory effusions (exudates), there is activation of coagulation with increased levels of fragment 1+2 and 
thrombin-antithrombin complex in addition to reduction of fibrinogen levels due to fibrinolysis and fibrin tissue incorporation. 
As a consequence, there is activation of the fibrinolytic system with increased levels of fibrin degradation products, including the 
D-dimer. These changes are not sufficient for differentiation of different subgroups of exudates. In transudates, these events were 
observed to a lesser degree.
CONCLUSION: The coagulation system plays an important role in the development of pleural diseases. Coagulation tests show 
differences between transudates and exudates but not among exudate subgroups. Understanding the physiopathological mechanisms 
of pleural disorders may help to define new diagnostic and therapeutic approaches.
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INTRODUCTION
The pleural layers covering the lungs (visceral) and the 
thoracic wall (parietal) define the pleural cavity, which is 
responsible for several important functions, including the 
maintenance of homeostasis. In this context, the interaction 
between immunologic and metabolic pleural factors should 
be considered. Their imbalance triggers a sequence of 
events that generally culminates with the development of a 
pleural effusion.1 According to the pathologic changes, the 
accumulated fluid is classified as a transudate (an imbalance 
between the hydrostatic and oncotic pressures in a normal 
pleura) or an exudate (an inflammatory process with pleural 
injury).
Characteristically, an exudative effusion demonstrates 
increased cellularity, protein levels and inflammatory 
markers.2,3 The contribution of the coagulation system 
is fundamental to the maintenance of homeostasis and 
should be considered due to its close relationship to the 
inflammatory process. The coagulation system prevents 892
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hemorrhage and initiates tissue repair and remodeling, in 
addition to orchestrating cellular proliferation, cellular 
migration and synthesis of inflammatory mediators. The 
coagulation system, when chronically activated and in the 
presence of an inflammatory state, can generate adverse 
effects such as chronic release of procoagulant factors (e.g., 
tissue factor), cellular activation (adhesion molecules), 
protein modulation (transformation of fibrinogen into fibrin), 
and even histological changes promoted by cytokines.4 All 
these changes in exudative effusions contribute to tissue 
remodeling and lead to pleural thickening, trapped lung 
and functional impairment.4 It is worth noting that chronic 
transudates, which have no inflammatory response, are 
rarely associated with pleural thickening.1 To recognize the 
contribution of the coagulation system to the differential 
diagnosis of pleural effusions, we evaluated the laboratory 
profiles of coagulation and fibrinolysis in pleural fluids of 
different etiologies.
MATERIALS AND METHODS
The present study was approved by the Research Ethics 
Committee of the University and informed written consent 
was obtained from the patients. Fifty-four patients with 
a diagnosed pleural effusion were sequentially selected: 
15 transudates and 39 exudates (9 parapneumonic, 15 
tuberculosis and 15 cancers). Inclusion was based on 
the presence of a defined etiology and the absence of 
coagulation disturbances: normal serum values for thrombin 
time (TT), activated partial thromboplastin time (APTT) 
and prothrombin time (PT). The presence of an associated 
pneumothorax determined exclusion.
The patients underwent thoracocentesis and, in some 
cases, a parietal pleural biopsy. Blood and fluid samples 
were collected at same time to differentiate transudate from 
exudates based on Light’s criteria.2 The etiological diagnosis 
of the exudates was established by considering, in addition 
to the clinical parameters, the following criteria:
*   Parapneumonic: radiological study compatible with 
pneumonia, neutrophilic pleural fluid with a positive 
culture or the presence of bacteria.
*   Tuberculosis: lymphocytic fluid (>80%) with rare meso-
thelial cells (<5%) and an elevated adenosine deaminase 
(> 40 Ul). The presence of Mycobacterium tuberculosis 
in the fluid, in the pleural fragment and/or granuloma 
(with or without caseation) in the histology.
*   Malignant: positive oncotic cytology in the fluid or in the 
pleural fragment.
Samples of blood and pleural fluid were collected 
in siliconated tubes containing citrate. Thrombin time, 
activated partial thromboplastin time and prothrombin 
time were immediately evaluated. Samples of fluid were 
centrifuged and frozen at - 80ºC for later measurement of 
fibrinogen, prothrombin fragment 1+2 (F1+2), thrombin-
antithrombin complex (TAT), fibrin degradation products 
(FDP) and D-dimer levels (enzymatic reaction - ELISA with 
photometric reading).
Statistical analysis
Data are presented as means and standard error. To 
compare the groups, Kruskal-Wallis non-parametric analysis 
of variance followed by Dunn’s test was performed. The 
power of the study was calculated to 0.8 and p-values 
lower than 0.05 were considered significant. The statistical 
program used was Systat Software 2006 (Sigma Stat 3.5; 
California, USA).
RESULTS
All patients had normal blood coagulation profiles. 
Irrespective of etiology, the pleural fluid samples showed 
higher prothrombin times (PT) and activated partial 
thromboplastin (aPTT) than those observed in blood.
With respect to plasma, the pleural levels of fibrinogen 
were reduced (transudates and exudates), while in all other 
tests, the levels were increased. Significant differences 
were observed in the pleural levels of fibrinogen between 
transudates and exudates (p = 0.004) and also among 
transudates and parapneumonic effusions (p = 0.011) 
secondary to tuberculosis (p = 0.023) and cancer (p = 0.005). 
Comparison among the exudates did not show statistically 
significant differences (p = 0.214); Figure 1.
For the levels of fragment 1+2, we noted results inverse 
to those observed fibrinogen. The transudates presented a 
significant reduction with respect to the exudates (p = 0.001) 
and the parapneumonic effusions (p = 0.0037) secondary to 
tuberculosis (p < 0.001) and cancer (p = 0.002). There were 
no differences among the exudates (p = 0.391); Figure 1.
The thrombin-antithrombin complex showed changes 
similar to F1+2, with a statistically significant increase 
in exudates as compared to transudates (p < 0.001). 
Similarly, there were differences among transudates 
and parapneumonic effusions (p = 0.017) secondary 
to tuberculosis (p < 0.001) and cancer (p = 0.001). No 
significant differences were observed among the exudates 
(p = 0.094); Figure 2.
The values for fibrin degradation products were not 
different between transudates and exudates (p = 0.42), 
transudates and parapneumonic effusions (p = 0.068), or 
secondary to tuberculosis (p = 0.798) and cancer (p = 0.933). 
Similar findings were observed with respect to D-dimer, 893
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with no significant differences observed between transudates 
and exudates (p = 0.277) or parapneumonic effusions (p = 
0.811), or secondary to tuberculosis (p = 0.213) and cancer 
(p = 0.053); Figure 2.
DISCUSSION
This study demonstrates that the coagulation system 
behaves differently in transudates and exudates, reflecting 
the  pathophysiologic  mechanisms  involved  in  the 
development of pleural effusions. This may be an important 
addition to the methods for its diagnosis.5,6
In transudates, there is no increase in protein and 
cellular permeability, nor is there an inflammatory response 
or activation of the coagulation cascade. Homeostasis is 
disrupted by the imbalance between pressure and oncotic 
forces, resulting in fluid accumulation with minimal 
substrate (proteins) and reduced or absent stimuli for 
structural changes.
It has been well documented that inflammatory cytokines 
play important roles in the coagulation and fibrinolytic 
systems, which, in turn, influence the inflammatory 
process. This inflammation-coagulation relationship is of 
fundamental importance to the pathophysiology of pleural 
Figure 1 - Fibrinogen and fragment 1+2 levels (mean ± standard error) in 
transudates, exudates (E), parapneumonic (P), tuberculosis (Tb) and cancer 
(M). * p < 0.05 (x transudate)
Figure 2 - Thrombin-antithrombin complex (TAT), products of the fibrin 
degradation (FDP) and D-dimer levels (mean ± standard error) in transudates, 
exudates (E), parapneumonic (P), tuberculosis (Tb) and cancer (M). * p < 
0.05 (x transudate)894
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effusions. The inflammatory response that follows the 
injury is essential in the tissue repair phase. In this context, 
fibrin deposition represents the substrate for anatomical 
reorganization and repair.1,7 However, depending on several 
factors, e.g., the intensity and persistence of injury, simple 
repair (restitutio ad integrum) may be replaced by fibrosis 
with pleural thickening and synechiae. 
Following tissue injury, vasodilatation secondary to 
the inflammatory process facilitates the passage of plasma 
and proteins into the tissue. The binding of tissue factor 
with factor VII (present in the plasma) forms a complex, 
activating and initiating the coagulation cascade culminating 
in the activation of factor X. When this factor acts on 
prothrombin, it is cleaved into two parts: thrombin and 
fragment 1+2; this reflects the activation of coagulation. 
Thrombin, acting directly on fibrinogen, produces fibrin, 
which is ultimately responsible for pleural thickening. 
The maintenance of physiological balance is dependent 
on coagulation inhibitors (antithrombin, C and S proteins). 
Antithrombin plays an important role by linking itself 
to thrombin, thus, forming the thrombin-antithrombin 
complex and blocking thrombin activity. However, once 
fibrin is formed, the physiological balance is weighted 
toward lysis (fibrinolysis). In the presence of fibrinolytic 
activity, an increase in FDP and D-dimer values is observed; 
the latter being specific to the lysis of polymerized and 
stabilized fibrin. Inflammatory processes may interfere in 
the coagulation cascade modifying the reparatory tissue 
response.8,9 In parapneumonic or hemorrhagic effusions, 
for example, the exaggerated deposition of fibrin frequently 
produces pleural thickening and septations or loculations.1
The results obtained show that in pleural effusions, the 
coagulation and fibrinolysis profiles reflect the status of the 
pleural layers. Among inflammatory effusions (exudates), 
there is coagulation activation due to the production of 
thrombin (characterized by the increase of F1+2) and 
reduction in the levels of fibrinogen (resulting from its 
consumption). As expected, this determines the activation of 
the fibrinolytic (increased levels of FDP and D-dimer) and 
anticoagulation (increased TAT) systems as a counterbalance 
to the procoagulation cascade. The increased formation of 
fibrin is part of the pathophysiologic mechanism of exudates 
and is confirmed in the analysis of loculated effusions, which 
show higher levels of inflammatory markers and lower 
fibrinolytic activity.10
We speculate that fibrin tissue incorporation as well 
as fibrinolytic activity occurring in the pleural cavity and 
observed predominantly in exudates may explain the low 
concentrations of fibrinogen and increased levels of D-dimer, 
fibrin degradation products and fragment 1+2.
Routine coagulation tests (PT, TT and APTT) are not 
adequate to recognize hypercoagulable states. However, they 
are specific for identifying coagulation deficiency factors in 
patients with hemorrhagic diseases. The patients in this study 
showed no changes in routine coagulation tests.
The increased levels of fibrin degradation products in 
malignant and infectious effusions (when compared to 
transudates) described by Asted et al.9 were not observed in 
the present study. It is of interest that our results, including 
those obtained with transudates, show increase levels of 
fibrin degradation products and D-dimer values, likely 
reflecting homeostatic degradation of coagulation proteins.
Special characteristics have been described for malignant 
effusions. High levels of fibrin degradation products and 
fragment 1+2 (markedly higher than in serum levels) reveal 
greater activity of the coagulation system in the pleural 
space, suggesting participation of this system in invasive 
cancer.4,11,12 These findings, which denote a predominance of 
procoagulant activity, were not demonstrated in the present 
study.
CONCLUSION
Based on the results of this study, we conclude that 
the coagulation system plays an important role in pleural 
diseases and that the understanding of pathophysiological 
mechanisms may open possibilities for new diagnostic and 
therapeutic approaches. Differences were observed between 
transudates and exudates, but not among subgroups of 
exudates. In transudates, the lower coagulation protein influx 
and the decreased degradation/activation reflect a lesser 
degree of injury and inflammatory activity. Since there is 
little or no injury, the coagulation system is not activated and 
less reparative action and remodeling occur, diminishing the 
probability of pleural thickening or loculations. 
More studies are needed to determine whether different 
etiologies of exudative pleural diseases affect the coagulation 
system.
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